 Exelixis Incs NASDAQ: EXEL collaborating partner Takeda Pharmaceutical Co Ltd NYSE: TAK and Ono Pharmaceutical Co Ltd have received approval for Cabometyx cabozantinib in Japan. The approval covers Cabometyx combined with Bristol-Myers Squibb Cos NYSE: BMY Opdivi nivolumab for unresectable or metastatic renal cell carcinoma RCC. 